China-based Gan & Lee Pharmaceuticals has dosed the first participant in a Phase I study of GZC8072, an oral peptide GLP-1 receptor agonist engineered for once-weekly administration. The candidate targets type 2 diabetes and weight management in people with obesity or overweight.

GLP-1 receptor agonists are the drug class behind semaglutide and tirzepatide. GLP-1 itself is an incretin hormone secreted from intestinal L-cells that stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts centrally to reduce appetite.

The half-life problem

Native GLP-1 has a plasma half-life of roughly one to two minutes because dipeptidyl peptidase-4 cleaves it almost immediately, which makes the unmodified hormone clinically unusable. Approved peptide agonists get around this with fatty acid conjugation that enables albumin binding, the basis for semaglutide's approximately 160-hour half-life.

Gan & Lee says GZC8072 uses a different route, built on two proprietary platforms it calls NovaPeptide, intended to extend peptide half-life, and SupOraTide, designed to improve oral bioavailability. The company says the combination produces enhanced intrinsic receptor activity, a prolonged half-life, and enough oral absorption to support weekly dosing. Preclinical pharmacokinetic data have not been publicly disclosed.

What the trial actually measures

Study CTR20263271 is a multicenter, randomized, double-blind, placebo-controlled Phase I trial enrolling 112 participants. A single ascending dose portion will evaluate safety and tolerability in healthy adults, and a multiple ascending dose portion will enroll participants with overweight or obesity.

Primary endpoints cover safety and tolerability, with pharmacokinetic and pharmacodynamic data collected alongside. That is a first-in-human design doing exactly what it should, and it is worth being clear that nothing here tests weight or glucose outcomes.

A crowded oral race

Oral semaglutide (Rybelsus) is already approved for type 2 diabetes, using the absorption enhancer SNAC and requiring fasting administration with limited water, and the FDA approved oral semaglutide tablets under the Wegovy brand for obesity management on December 22, 2025. Eli Lilly's orforglipron (Foundayo), a non-peptide small molecule, was approved in April 2025.

Innovent Biologics' IBI3042, an oral non-peptide small molecule also designed for weekly dosing, entered first-in-human testing this month. GZC8072's peptide chemistry is what separates it from that approach.

Bottom line

The case for convenience is real: reported real-world adherence to injectable GLP-1 agonists at six months sits at 58 to 69 percent. Whether the delivery platforms deliver bioavailability sufficient for clinically meaningful receptor engagement is the question Phase I data have to answer.